Cargando…
De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?
The synergistic blockade of the key platelet signaling pathways of cyclooxygenase-1 blockade and P2Y(12) signaling by combining aspirin plus a potent P2Y(12) inhibitor (prasugrel or ticagrelor), the so called dual antiplatelet treatment (DAPT), has represented the antithrombotic regimen of choice in...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452742/ https://www.ncbi.nlm.nih.gov/pubmed/36093167 http://dx.doi.org/10.3389/fcvm.2022.975969 |